Levodopa/Benserazide Teva Uk (Benserazide Hydrochloride, Levodopa)

Levodopa is a precursor of dopamine that crosses the blood‑brain barrier. Once inside the central nervous system, it is converted to dopamine, compensating for the neurotransmitter loss characteristic of Parkinson's disease. Benserazide blocks peripheral conversion, ensuring more levodopa reaches the brain.

The dosage of Levodopa/Benserazide is individualized and determined by the prescribing clinician based on disease severity, patient response, and tolerability. Patients should follow the specific dosing regimen provided by their healthcare professional and not adjust the dose without medical advice.

The safety of Levodopa/Benserazide in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levodopa/Benserazide is considered the most effective symptomatic therapy for Parkinson's disease because it directly replenishes dopamine. Other classes, such as dopamine agonists or MAO‑B inhibitors, may be used as adjuncts or early‑stage options, but they generally provide less robust motor improvement than the levodopa‑benserazide combination.

Levodopa/Benserazide tablets should be stored at room temperature, below 25 °C, in their original packaging. Keep them away from excess moisture and direct sunlight to maintain product stability throughout its shelf life.

Levodopa/Benserazide is taken orally, usually with a glass of water. It may be recommended to take the medication with food or on an empty stomach depending on the prescriber's guidance, as food can affect absorption.

Serious risks include the development of dyskinesias (involuntary movements), severe hypotension, and psychiatric effects such as hallucinations or confusion. Patients should be monitored regularly for these events, and any sudden changes should be reported to a healthcare professional promptly.

Levodopa/Benserazide is contraindicated in patients with known hypersensitivity to levodopa, benserazide, or any excipients in the formulation. It should also be avoided in individuals taking non‑selective MAO inhibitors due to the risk of hypertensive crisis.